You are here

Article Text

Article menu
Download PDFPDF
Letters to the editor
Mirena® removal from a nulliparous woman: response from Bayer HealthCare
  1. Amit Aggarwal, MA, MBBS1,
  2. Pirjo Inki, MD, PhD2,
  3. Jussi Pirjola3
  1. Senior Medical Advisor, Women's Health, Bayer HealthCare Pharmaceuticals, Newbury, UK; amit.aggarwal@bayer.com
  2. Global Medical Lead IUS Family, Global Medical Affairs, Women's Health, Bayer HealthCare Pharmaceuticals, Turku, Finland; pirjo.inki@bayer.fi
  3. Director, Quality Management, Bayer HealthCare Pharmaceuticals, Turku, Finland; jussi.pirjola@bayer.com

https://doi.org/10.1136/jfprhc-2011-100155

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank you for the opportunity to respond to Dr Manning's letter, published in this issue of the Journal.1

    Bayer HealthCare Pharmaceuticals Quality Assurance unit has previously received isolated reports of similar cases, also usually associated with difficult removal …

    View Full Text

    Footnotes

    • Competing interests The authors are all employees of Bayer HealthCare Pharmaceuticals, the manufacturer of Mirena®.